Immuneering Corporation2024财年第三财季实现净利润-14.60百万美元，同比减少15.87%

市场透视11-16

11月16日，Immuneering Corporation（IMRX.US）公布财报，公告显示公司2024财年第三财季净利润为-14.60百万美元，同比减少15.87%；其中营业收入为0.00美元，每股基本收益为-0.49美元。从资产负债表来看，Immuneering Corporation（IMRX.US）总负债10.84百万美元，其中短期债务324702.00美元，资产负债比为6.33，...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2483153400?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-11-16 07:02","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2483153400","market":"us","top_or_hot":-1,"title":"Immuneering Corporation2024财年第三财季实现净利润-14.60百万美元，同比减少15.87%","media":"市场透视","content":"<div>\n<p>11月16日，Immuneering Corporation（IMRX.US）公布财报，公告显示公司2024财年第三财季净利润为-14.60百万美元，同比减少15.87%；其中营业收入为0.00美元，每股基本收益为-0.49美元。从资产负债表来看，Immuneering Corporation（IMRX.US）总负债10.84百万美元，其中短期债务324702.00美元，资产负债比为6.33，...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241116070242abc5c82e&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Immuneering Corporation2024财年第三财季实现净利润-14.60百万美元，同比减少15.87%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nImmuneering Corporation2024财年第三财季实现净利润-14.60百万美元，同比减少15.87%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-16 07:02 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241116070242abc5c82e&s=b><strong>市场透视</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>11月16日，Immuneering Corporation（IMRX.US）公布财报，公告显示公司2024财年第三财季净利润为-14.60百万美元，同比减少15.87%；其中营业收入为0.00美元，每股基本收益为-0.49美元。从资产负债表来看，Immuneering Corporation（IMRX.US）总负债10.84百万美元，其中短期债务324702.00美元，资产负债比为6.33，...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241116070242abc5c82e&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IMRX","symbol_name":"Immuneering Corp","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241116070242abc5c82e&s=b","article_id":"2483153400","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241116070242abc5c82e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2483153400","pubTimestamp":1731711761,"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"11月16日，Immuneering Corporation公布财报，公告显示公司2024财年第三财季净利润为-14.60百万美元，同比减少15.87%；其中营业收入为0.00美元，每股基本收益为-0.49美元。从资产负债表来看，Immuneering Corporation总负债10.84百万美元，其中短期债务324702.00美元，资产负债比为6.33，流动比率为7.99。机构评级：截至2024年11月16日，当前有6家机构对Immuneering Corporation目标价做出预测，其中目标均价为11.08美元，其中最低目标价为1.50美元，最高目标价为25.00美元。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":["earning"],"viewcount":null,"language":"zh","relate_stocks":{"IMRX":"Immuneering Corp"},"translate_title":"Immuneering Corporation achieved net profit of-US $14.60 million in the third fiscal quarter of fiscal year 2024, a year-on-year decrease of 15.87%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IMRX":1},"content_text":"11月16日，Immuneering Corporation（IMRX.US）公布财报，公告显示公司2024财年第三财季净利润为-14.60百万美元，同比减少15.87%；其中营业收入为0.00美元，每股基本收益为-0.49美元。从资产负债表来看，Immuneering Corporation（IMRX.US）总负债10.84百万美元，其中短期债务324702.00美元，资产负债比为6.33，流动比率为7.99。机构评级：截至2024年11月16日，当前有6家机构对Immuneering Corporation目标价做出预测，其中目标均价为11.08美元，其中最低目标价为1.50美元，最高目标价为25.00美元。公司简介：Immuneering Corp是一家生物制药公司。该公司专注于通过在药物开发过程的每个阶段应用深入的转化生物信息学知识，改善一系列具有破坏性的肿瘤学和神经学疾病患者的预后。该公司拥有独有的计算性疾病抵消技术平台，可实现Immuneering的药物发现项目。该公司还为制药和生物技术公司提供无与伦比的计算生物学能力。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2483153400"}